CompanyGraph
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 4.55: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.27%
Annual Rate
TRY 0.03Paid semi-annual
Payout Ratio
7.8%Sustainable
Last Ex-Dividend
Aug 4, 2026
The reported statements, read against the company's own industry.
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
Financials view
Market Capitalization
54.56BTRY1.14B · vs all stocks (USD)
Trailing P/E
52.57xRevenue (TTM)
22.17BTRY461.26M · vs all stocks (USD)
Profit Margin
5.21%Beta
-0.0520xvs all stocks
52-Week Change
-9.78%vs all stocks
Forward Annual Dividend Yield
0.27%vs all stocks
Market Capitalization
54.56BTRY1.14B · vs all stocks (USD)
Enterprise Value
59.49BTRY1.24B · vs all stocks (USD)
Trailing P/E
52.57xPEG Ratio
2.79xPrice to Sales (TTM)
2.45xPrice to Book (MRQ)
4.16xEnterprise to Revenue
2.68xEnterprise to EBITDA
20.34xGross Margin
29.45%Profit Margin
5.21%Operating Margin
10.98%Return on Assets (TTM)
7.99%Return on Equity (TTM)
10.46%Revenue (TTM)
22.17BTRY461.26M · vs all stocks (USD)
Revenue per Share (TTM)
4.13TRYUpdated Aug 21, 2026Quarterly Revenue Growth
22.90%Gross Profit (TTM)
5.24BTRY109.06M · vs all stocks (USD)
EBITDA (TTM)
3.04BTRY63.25M · vs all stocks (USD)
Net Income (TTM)
1.16BTRY24.04M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
377.10%Operating Cash Flow (TTM)
1.29BTRY26.85M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-4.38BTRY-91.24M · vs all stocks (USD)
Forward Annual Dividend Rate
0.0323TRYUpdated Aug 21, 2026Forward Annual Dividend Yield
0.27%vs all stocks
Trailing Annual Dividend Rate
0.0250TRYUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.21%vs all stocks
Payout Ratio
7.79%Minority Interest (Equity)
-6.85MTRYFY2025 · Dec 31, 2025Revenue
19.18BTRYFY2025 · Dec 31, 2025Cost of Goods Sold
15.16BTRYFY2025 · Dec 31, 2025Gross Profit
4.02BTRYFY2025 · Dec 31, 2025Operating Income
2.47BTRY51.40M · vs all stocks (USD)
Pre-tax Income
1.49BTRYFY2025 · Dec 31, 2025Income Tax Expense
680.24MTRYFY2025 · Dec 31, 2025Net Income
805.68MTRYFY2025 · Dec 31, 2025EBIT
2.41BTRYFY2025 · Dec 31, 2025EBITDA (Income Statement)
2.87BTRYFY2025 · Dec 31, 2025Research & Development
685.71MTRYFY2025 · Dec 31, 2025Selling, General & Administrative
777.53MTRYFY2025 · Dec 31, 2025Other Operating Expenses
354.64MTRYFY2025 · Dec 31, 2025Non-operating Interest Income
573.54MTRYFY2025 · Dec 31, 2025Non-operating Interest Expense
921.34MTRYFY2025 · Dec 31, 2025Net Income from Continuing Operations
814.44MTRYFY2025 · Dec 31, 2025Minority Interests (P&L)
8.76MTRYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00TRYFY2025 · Dec 31, 2025Operating Cash Flow
619.34MTRYFY2025 · Dec 31, 2025Free Cash Flow
617.74KTRYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
93.97MTRYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
814.44MTRYFY2025 · Dec 31, 2025Other Non-cash Items
464.22MTRYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-213.68MTRYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-445.64MTRYFY2025 · Dec 31, 2025Capital Expenditures
-618.72MTRYFY2025 · Dec 31, 2025Net Intangibles (CF)
-365.70MTRYFY2025 · Dec 31, 2025Other Investing Activity
-314.56KTRYFY2025 · Dec 31, 2025Net Investing Cash Flow
-619.03MTRYFY2025 · Dec 31, 2025Other Financing Charges
2.64MTRYFY2025 · Dec 31, 2025Net Financing Cash Flow
2.64MTRYFY2025 · Dec 31, 2025Shares Outstanding
4.49BSharesUpdated Aug 21, 2026Float Shares
298.57MSharesUpdated Aug 21, 2026% Held by Insiders
72.50%vs all stocks
% Held by Institutions
4.06%vs all stocks
Total Cash (MRQ)
228.89MTRY4.76M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.0510TRYUpdated Aug 21, 2026Total Debt (MRQ)
5.32BTRY110.78M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.4079xCurrent Ratio (MRQ)
1.29xBook Value per Share (MRQ)
2.90TRYUpdated Aug 21, 2026Total Assets
19.45BTRY404.72M · vs all stocks (USD)
Total Current Assets
9.87BTRYFY2025 · Dec 31, 2025Total Liabilities
9.12BTRYFY2025 · Dec 31, 2025Total Non-current Assets
9.58BTRYFY2025 · Dec 31, 2025Total Non-current Liabilities
1.35BTRYFY2025 · Dec 31, 2025Total Current Liabilities
7.77BTRYFY2025 · Dec 31, 2025Cash
75.96MTRYFY2025 · Dec 31, 2025Cash Equivalents
18.01MTRYFY2025 · Dec 31, 2025Cash & Cash Equivalents
93.97MTRYFY2025 · Dec 31, 2025Other Short-term Investments
2.04BTRYFY2025 · Dec 31, 2025Accounts Receivable
2.08BTRYFY2025 · Dec 31, 2025Inventory
2.34BTRYFY2025 · Dec 31, 2025Accounts Payable
3.18BTRYFY2025 · Dec 31, 2025Short-term Debt
2.90BTRYFY2025 · Dec 31, 2025Long-term Debt
239.83MTRYFY2025 · Dec 31, 2025Common Stock (Book)
4.50BTRYFY2025 · Dec 31, 2025Retained Earnings
3.52BTRYFY2025 · Dec 31, 2025Total Shareholders' Equity
10.33BTRY214.93M · vs all stocks (USD)
Treasury Stock
93.21MTRYFY2025 · Dec 31, 202552-Week Low
7.12TRYUpdated Aug 21, 202652-Week High
14.93TRYUpdated Aug 21, 202652-Week Change
-9.78%vs all stocks
Beta
-0.0520xvs all stocks
50-Day MA
9.46TRYUpdated Aug 21, 2026200-Day MA
9.98TRYUpdated Aug 21, 2026Avg 10-Day Volume
70.87MSharesUpdated Aug 21, 2026Avg 30-Day Volume
48.95MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
0.2300TRYUpdated Aug 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Revenue is growing, but receivables have grown faster over the last six to eight yearsSignificant
Revenue Growth YoY: 0.23Receivables vs revenue divergence: 7.28
Financial Health
Altman Z-Score 4.55: safe zoneNotable
Altman Z-Score: 4.55
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
SSY Group Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow
Savara Inc.
Tier 1ProductionApproval-Gated PipelineRule
Alvotech S.A.
Tier 1ProductionApproval-Gated PipelineRule
Capricor Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Innovita Biological Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sino Medical Sciences Technology Inc.
Tier 1ProductionApproval-Gated PipelineRule
Wave Life Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
MeiraGTx Holdings plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shantou Institute of Ultrasonic Instruments Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Frontier Biotechnologies Inc.
Tier 1ProductionApproval-Gated PipelineRule